Promontory Therapeutics Inc. is a privately held, clinical stage pharmaceutical company focused on small molecule immunotherapy. The company's lead candidate, PT-112, is the first small molecule conjugate of pyrophosphate in oncology and possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD), through the release of damage associated molecular patterns (DAMPs) that bind to pattern recognition receptors on dendritic cells and promote the adaptive immune response in the tumor microenvironment. Clinical data generated across three Phase 1 studies have demonstrated single-agent anti-cancer activity and an attractive tolerability profile. Three Phase 2 studies of PT-112 are underway, including in NSCLC; with the NCI utilizing PT-112 in thymic epithelial tumors where PT-112 has received Orphan Drug designation; and in mCRPC designed to lead to a pivotal trial in this indication with high unmet medical needs and limited therapeutic options.
